Because fibrin is commonly observed within arthritic joints, studies were undertaken to determine whether purified coagulation and fibrinolytic proteases degrade cartilage in vitro and to seek evidence for the activation of coagulation in arthritic joints through measurements of the levels of inhibitor-enzyme complexes and several other proteins associated with coagulation and fibrinolysis. The concentrations of 13 plasma proteins and complexes of thrombin and Factor Xa with antithrombin III were measured in synovial fluids recovered at the time of knee replacement surgery. All zymogens necessary to constitute the coagulation cascade were present. Thrombin and the combination of prothrombin plus prothrombinase induced proteoglycan release from both normal and arthritic cartilages. Factor Xa and plasmin induced release from diseased cartilage only, and urokinase, tissue plasminogen activator, and activated protein C were without effect at the levels used. At saturating levels of thrombin (-2.0 ,uM) 80% of the proteoglycan content of normal cartilage was released within 24 h. Thrombin, which is cationic, reversibly binds cartilage with Kd = 7.0±1.0 ,uM and B__ = 820±70 ng/mg of human cartilage. Levels of thrombin-antithrombin m complexes in synovial fluids and arthritis were 4-fold higher in osteo(OA) and 43-fold higher in rheumatoid(RA) than in controls (0.98 nM). Factor Xaantithrombin III complex levels were threefold lower in OA and fivefold higher in RA than in controls (0.24 nM). These elevated levels of enzyme-inhibitor complexes imply a history of activation of coagulation within the joint, especially in RA. Since thrombin degrades cartilage in vitro and had been generated in vivo, as inferred by the existence of thrombin-antithrombin m complexes, intraarticular activation of coagulation may both contribute to the pathology of arthritis and comprise a target for therapy and diagnosis. (J. Clin. Invest. 1994. 94:472-480.)
Introduction
Both rheumatoid and osteoarthritis (RA and OA)' are characterized by disruption of articular cartilage, considerable pain, and impairment of the use of affected joints ( 1, 2) . Although a great deal of effort has been expended to determine the mechanisms responsible for cartilage destruction, and considerable progress has been made, the mechanism or mechanisms which ultimately underlie the phenomenon are not known (1) (2) (3) . Most work to date, however, suggests that the destruction of cartilage in arthritis can be attributed substantially to inappropriate expression of proteolytic activity within the joint space and extracellular matrix. This may be coupled with either suppressed (RA) or enhanced (OA) synthesis of matrix components (1) .
The integrity of cartilage and thus its ability to perform its mechanical function is maintained by a dynamic balance between synthesis and degradation of components of the extracellular matrix by factors elaborated by the chondrocytes. Among these factors are the latent neutral metalloproteinases procollagenase, progelatinase, and prostromelysin which, when activated, can catalyze the degradation of collagen and proteoglycans (4, 5) . The enzymes derived from these zymogens may be neutralized by inhibitors released from chondrocytes (6, 7) .
In an inflammatory milieu, the immune system also may participate in cartilage destruction, especially in RA in which monocytes, macrophages and neutrophils infiltrate the tissues of the joint and the joint fluid (8) . These cellular elements can both elaborate mediators which influence the metabolic function of chondrocytes (e.g., interleukin 1, tumor necrosis factor, prostaglandins) and provide enzymes capable of activating latent metalloproteinases (8) (9) (10) . Elastase, liberated by the polymorphonuclear neutrophil, has been detected in the synovial fluids of rheumatoid and osteoarthritic joints at respective activity levels 10-and 100-fold greater than that of plasma ( 11 ). The potential also exists for the involvement of proteases of the fibrinolytic or coagulation systems in cartilage destruction. The ultimate enzyme of fibrinolysis, plasmin, not only catalyzes the activation of procollagenase and prostromelysin (12) but also directly catalyzes degradation of proteoglycans in vitro ( 13, 14) . In addition, plasmin-derived fibrin degradation products have been detected in the synovium and synovial fluid of patients with rheumatoid arthritis (15, 16) . Although activated clotting factors have not been reported in the diseased joint, Weinberg et al. ( 17) recently demonstrated by histological techniques the presence of fibrinogen, tissue factor, Factor XIII, cross-linked fibrin (D-dimer), urokinase-like plasminogen activator and alpha2-antiplasmin. In addition, the nearly universal existence of fibrin in the cartilage and synovial tissue in RA joints (8, 18) , and its frequent presence in OA (19) , indirectly indicates that thrombin activity is expressed in these diseases.
Since thrombin is formed only by activation of its plasma precursor prothrombin (20), the presence of fibrin also suggests intraarticular activation of the coagulation cascade. That activation of coagulation in the diseased joint could occur is plausible, since plasma components are known to enter inflamed joints (8) . In addition, activated monocytes are present to both supply tissue factor to initiate the extrinsic pathway and, along with platelets and neutrophils, provide the surface components required for the assembly of the Factor X and prothrombin-activating complexes (21) (22) (23) . Thus, considerable published work indicates the potential within the diseased joint for expression of activities associated with both coagulation and fibrinolysis and a milieu conducive to their continued activation.
The purposes of this study were to determine whether specific purified coagulation and fibrinolytic proteases promote cartilage degradation in vitro and to examine synovial fluids for evidence of intraarticular coagulation in arthritis. The results indicate that the purified enzyme thrombin can interact with cartilage and induce its degradation in vitro. The zymogens of the coagulation cascade were found in substantial levels in the fluids of diseased joints, suggesting a potential for thrombin generation. In addition, covalent complexes of Factor Xa and thrombin with their physiologic inhibitor, antithrombin III, were found at elevated levels in synovial fluids of OA and RA joints, indicating that the coagulation cascade had been activated in those joints.
Methods
Materials. The human plasma proteins used in this study were all purified to apparent homogeneity as indicated by electrophoresis. Factor X, prothrombin, and protein C were isolated from eluates of barium citrate precipitates of human plasma by chromatography on DEAE-fast flow Sepharose and dextran sulphate agarose (24, 25) . Bovine Factor V was isolated as described previously (26) . Plasminogen was isolated by affinity chromatography on lysine Sepharose, and plasmin was prepared with urokinase and re-chromatography on lysine Sepharose (27, 28) .
Factor Xa was prepared by incubating Factor X with the purified Factor X activator from Russell's Viper Venom, and subsequent affinity chromatography on benzamidine Sepharose (29) . Thrombin was prepared by activating prothrombin with prothrombinase (Factor Xa, Factor Va, phospholipid vesicles, and Ca2+) and isolating the enzyme by chromatography on SPC-50 Sephadex (30). '25I-labeling of thrombin was accomplished by the lodobead method (Pierce Chemical Co., Rockford, IL). Briefly, two iodobeads were rinsed in 1.0 ml of 0.015 M Tris-HCl, 0.1 M NaCl, pH 7.4. The buffer was discarded and 0.5 ml of fresh buffer was added, followed by 1.0 mCi of Na 1251 (ICN Radiochemicals, Irvine, CA). The mixture was shaken intermittently for 5 min at 22'C.
The buffer plus Na '251 were transferred into 0.5 ml of thrombin solution (740 ,g/ml) in the same buffer. The reaction was carried out at 22°C for 10 min. The products were separated by gel filtration on a column of Sephadex G-25. The specific-radioactivity was 2.2-2.4 x 106 cpml Mg of thrombin. The 125I-labeled thrombin prepared by this method comigrated with unlabeled thrombin on SDS-PAGE and was active in a thrombin clotting assay. Radiolabeled thrombin was mixed with unlabeled thrombin to yield a final specific radioactivity of 1.2-2.7 x 105 cpm/Ivg. Factor Va was prepared by activation of Factor V by thrombin (26) . Fibrinogen was isolated by the method of Straughn and Wagner (31 ) . Antithrombin III was isolated by affinity chromatography on Heparin Sepharose (32) . Activated protein C was prepared by incubation of thrombin with subsequent removal of thrombin on SPC-50 Sepharose (25) . Tissue plasminogen activator (Activase) was a generous gift from Dr. Gordon Veher of Genentech Inc., San Francisco, CA, and urokinase was purchased from Calbiochem, San Diego, CA. Procoagulant phospholipid (PCPS) vesicles were prepared from phosphatidylserine and phosphatidylcholine (1:3) by sonication and ultra centrifugation (33) . The irreversible chloromethyl ketone thrombin inhibitor (PPA-CK) was obtained from Calbiochem. The sheep anti-human thrombin, goat antihuman Factor X and sheep anti-human antithrombin III affinity-purified polyclonal antibodies and all other antibodies were supplied by Affinity Biologicals (Hamilton, Ontario, Canada).
Cartilage. Specimens of normal adult bovine cartilage were excised under aseptic conditions from metacarpophalangeal joints obtained fresh from the abattoir (McFedridge Meats, Glenburnie, Ontario). Normal human cartilage specimens, when used, were obtained at autopsy from knees of individuals lacking clinical evidence of joint disease. Diseased specimens were obtained from resected tissue of patients undergoing total knee replacement. No special efforts were made to collect either more or less damaged cartilage in the diseased specimens. In all, samples from 11 patients with rheumatoid arthritis, 23 with osteoarthritis, and 5 controls (cadaver) were obtained. Full-depth plugs of 5 mm diameter were cut with a coring tool, preweighed, and then stabilized for 24 h in serum-free Dulbecco's medium (Flow Laboratories, McLean, VA) supplemented with 10 mM Hepes, penicillin (100 U/ml) and streptomycin (100 Mg/ml) at 370C. In some experiments the samples of cartilage were subjected to three freeze-thaw cycles in liquid nitrogen to selectively kill chondrocytes, or heated at 60C for 30 min to inactivate all intra-and extracellular activities (34) .
Synovial fluids. Samples of synovial fluids were collected from RA and OA patients at the time of knee replacement and from control (cadaver) joints. Fluids were collected into vacutainer tubes (Becton Dickinson Vacutainer Systems, Rutherford, NJ) containing EDTA (K3) and centrifuged for 5 min at 6,600 g at 220C. Supernatants were collected and immediately frozen at -70°C until used.
The effects of coagulation and fibrinolytic enzymes on the release of proteoglycans from cartilage. Cartilage explants were incubated for 24 h with the following alternative reagents: (a) Factor Xa (10 nM); (f) thrombin (0-10 uMM); or (g) prothrombin (0.1 I M) plus prothrombinase ( 10 nM Factor Xa, 10 nM Factor V, 10 M1M PCPS vesicles, and 5 mM Ca2+). The concentrations of the proteins were calculated from measurements of absorbance at 280 nm and published extinction coefficients and molecular weights. After the incubation, samples of the media were collected and analyzed for proteoglycan (glycosaminoglycan) content by the 1,9-dimethylmethylene blue dye (DMB) binding assay (35) . The DMB assay was performed in a 96-well microtiter plate. The samples were diluted 1:16 with DMB solution (35) and absorbances at 535 nm were immediately measured on a Titertek Multiscan MCC/340 ELISA Reader. A standard curve was prepared using chondroitin sulfate from bovine trachea (BDH Chemicals Ltd., Poole, England). The assay was linear for sample concentrations ranging from 5 to 250 '"g/ml.
Blanks consisted of the incubation medium only. Each experiment was performed at least twice and experimental measurements were duplicated within each of the experiments. Values reported are thus the mean and standard deviation of four measurements, unless otherwise stated.
Total proteoglycan content in cartilage was measured at the end of selected experiments. Plugs were blotted dry, weighed, and digested with papain at 65°C overnight. The papain solution was prepared by diluting a commercial papain suspension (Sigma Chemical Co., St. Louis, MO, P-3125) 1:50 in a buffer consisting of 0.075 M EDTA and 0.005 M cysteine HCl. The pH of this solution was adjusted to 6.5 with 1 N NaOH. 1.0 ml of this solution was added to each explant. After digestion the concentration of sulfated glycosaminoglycans (GAGS) in the medium was measured by the DMB assay as described above. Analysis of synovial fluids for levels of several plasma proteins and covalent complexes of thrombin and Factor Xa with antithrombin III. ELISA assays for numerous plasma coagulation and fibrinolytic zymogens and inhibitors were performed by conventional techniques. Results were compared to those obtained with pooled normal human plasma, used as a reference standard. Sandwich ELISA assays for complexes of antithrombin III with thrombin and Factor Xa were performed as described elsewhere (37) using 96-well Falcon plates (Becton Dickinson) that were precoated with either affinity-purified sheep anti-human thrombin or anti-human Factor X antibodies by incubation for either 2 h at 220C or overnight at 40C. The plates were blocked with 2% bovine serum albumin. Standard samples, made up in PBS (136 mM sodium chloride, 2.6 mM potassium chloride, 10 mM disodium hydrogen phosphate, 1.7 mM potassium dihydrogen phosphate, pH 7.4), supplemented with 1% bovine serum albumin, and the synovial fluid samples (diluted 1:200 for the Factor Xa-antithrombin III assay and diluted 1:4,000 for the thrombin-antithrombin III assay) were then incubated in the wells for 2 h at 220C. The fluids were then discarded and the wells were washed four times with PBS containing 0.5% (vol/vol) Tween 20 (PBS-Tween 20). Diluted, affinity purified, anti-human antithrombin III-horseradish peroxidase-conjugated antibody was added and incubated for 2 h at 22°C. The wells were again washed four times with PBS-Tween 20 buffer and once with H20. Then a 100-pl aliquot of a solution of ortho-phenylenediamine (0.4 mg/ml in 12 mM citric acid, 48 mM sodium phosphate, 0.03% H202, pH 5.0) was added and color development was monitored in a Titertek Twinreader (Flow Laboratories) at 450 nm. After the color had sufficiently developed, the reactions were stopped by the addition of 2.5 M H2SO4 (50 jl per well) and plates were read at 492 nm. Levels of enzyme-inhibitor complexes were quantified by reference to standard curves generated with purified antithrombin III Changes in wet weight over the 24-h incubation period also were determined for all cartilage specimens and enzymes. Normal human and bovine cartilages incubated with buffer typically lost 0.4-0.7% of their initial weight overnight. Specimens exposed to the enzymes showed weight losses ranging from 1.4-10.0% (thrombin); 2.4-3.1% (Factor Xa) and 3.0-4.4% (plasmin). The other enzymes did not yield weight losses significantly different from control levels. Diseased cartilages exhibited losses in weight also, although the changes were not identical to those obtained with normal tissues. In RA cartilage, weight losses of control specimens varied from 0.4-6.3%, whereas those obtained with the various enzymes were 10-15% (thrombin), 13-18% (plasmin), and 12.5-18% (Factor Xa). The one specimen of OA cartilage analyzed for weight loss showed no change with buffer; 8% with thrombin; 5% with Factor Xa; and 21% with plasmin.
The degradative potential of thrombin, plasmin and Factor Xa were further analyzed by incubation of the enzymes (in the presence or absence of Ca2+) with samples of cartilage previously subjected to freeze-thaw cycles or heated at 65°C as described in Methods. These experiments were performed to determine whether the activities of the enzymes were Ca2+ dependent; are expressed through secondary effects on latent metalloproteinases in the cartilage; or require the participation of viable chondrocytes. The results, (Fig. 1 ) indicate that thrombin (0.1 jaM) clearly induces proteoglycan release (up to 8.7 jg/mg wet) from control, freeze-thawed and heated specimens.
Plasmin and Factor Xa at the concentrations used, elicited less In spite of extensive washing, the solutions surrounding thrombin-treated cartilage clotted immediately. In addition, the control samples clotted in 2 h. Both the thrombin-treated and con- The existence of these complexes clearly indicates that the active enzymes Factor Xa and thrombin had existed within the synovial fluids of the diseased joints. In addition, the elevated levels of thrombin-antithrombin III complexes suggest that thrombin had been produced at higher rates or for longer periods in arthritic joints compared to controls, especially in rheumatoid arthritis. The data of Table II , in addition to indicating that the synovial fluids in arthritis possess components of coagulation cascade and that thrombin and Factor Xa had been present in these fluids, in most cases distinguish fluids from both diseases from normal fluids and, in some cases, distinguish the two disease fluids from one another. With the exception of the levels of al antitrypsin and Factor IX, the levels of all the proteins are significantly elevated relative to controls in rheumatoid fluids. In osteo fluids, the levels of von Willebrand Factor and protein C also are not significantly elevated compared to controls. The levels of von Willebrand Factor and protein C, however, are significantly different from one another when values in fluids from osteo and rheumatoid arthritis are compared. In addition, levels of the covalent complexes of Factor Xa and thrombin with antithrombin III are both significantly different when compared in the two diseases. Thus, some of these parameters, or collections of them, may be of value not only in identifying arthritis but also distinguishing osteo-from rheumatoid arthritis.
Discussion
The results of these studies indicate that thrombin, and the combination of prothrombin plus prothrombinase, rapidly in In inflammatory processes, activated leukocytes and endothelium express numerous components of both the coagulation and fibrinolytic pathways (40, 41) . Products of the coagulation and fibrinolytic reactions act to amplify the inflammatory reactions by attracting more inflammatory cells to the site through the chemotactic activities of thrombin (42) , fibrin(ogen) (43) , and fibrinogen-derived peptides (44) . Inflammatory mediators (TNF, IL-1) released from activated monocytes enhance expression of tissue factor in endothelial cells (45, 46) . In addition, Factor Xa stimulates release of endothelial cell mitogens (47) , and thrombin induces release of growth factor activities from several cell types (48) . Thus, these enzymes conceivably might contribute not only to the degradation of cartilage but also to the pathological proliferation of the synovium.
Work by others suggests a role for the fibrinolytic cascade in pathogenesis of RA and OA. The components of fibrinolytic system, plasminogen, plasminogen activators, and plasminogen activator inhibitor type 1 were found in diseased OA and RA cartilage (49, 50) . Plasmin mediates cartilage degradation in vitro, catalyzes degradation of proteoglycans, and activates la-tent metalloproteinases (12) (13) (14) . Moreover, plasmin derived fibrin degradation products have been detected in the synovium and synovial fluid of patients with RA (15, 16) . A similar role for coagulation proteases can be postulated from previous results and observations. The nearly universal existence of fibrin in the cartilage and synovial tissue in RA (8, 18) , and its frequent presence in OA (19) , strongly indicates intraarticular activation of the coagulation cascade and generation of thrombin. In addition, Weinberg et al. (17) , recently demonstrated in inflamed joints (OA and RA) enhanced expression of procoagulant molecules (fibrinogen, prothrombin, tissue factor, Factor XIII) which could contribute to the local pathology of the inflammation. In addition, Richardson et al. (51) , have shown that thrombin, in addition to plasmin, catalyzes proteoglycan degradation in the thoracic aorta of the rabbit. Our results show not only that components associated with coagulation including thrombin, Factor Xa, and prothrombin plus prothrombinase induce cartilage degradation in vitro, but also that thrombin and Factor Xa had been present in synovial fluids, as inferred by the presence of enzyme-inhibitor complexes. Together, these observations implicate intra-articular activation of the coagulation cascade as a potential contributor to cartilage destruction in arthritis.
Because anticoagulant therapy can both attenuate activation of coagulation and modify immunologically mediated inflammation (52, 53) , agents capable of preventing the intraarticular activation of coagulation may be useful in diminishing cartilage destruction in arthritis. In addition, the products of coagulation (and possibly fibrinolysis) in synovial fluids may have diagnostic value. For example, the elevated levels of thrombin-antithrombin III were clearly markers for arthritis, particularly rheumatoid arthritis, and some of the parameters indicated in Table  II not only correlated with arthritis but also distinguished the two types of arthritis.
